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Abstract: BACKGROUND: Although many patient, physician, and payment predictors of adherence have 
been described, knowledge of their relative strength and overall ability to explain adherence is limited. 
 
OBJECTIVES: To measure the contributions of patient, physician, and payment predictors in explaining 
adherence to statins 
 
RESEARCH DESIGN: Retrospective cohort study using administrative data 
 
SUBJECTS: 14,257 patients insured by Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) who 
were newly prescribed a statin cholesterol-lowering medication 
 
MEASURES: Adherence to statin medication was measured during the year after the initial prescription, 
based on proportion of days covered (PDC). The impact of patient, physician, and payment predictors 
of adherence were evaluated using multivariate logistic regression. The explanatory power of these 
models was evaluated with C statistics, a measure of the goodness of fit. 
 
RESULTS: Overall, 36.4% of patients were fully adherent. Older patient age, male gender, lower 
neighborhood percent black composition, higher median income, and fewer number of emergency 
department (ED) visits were significant patient predictors of adherence. Having a statin prescribed by 
a cardiologist, a patient's primary care physician, or a US medical graduate were significant physician 
predictors of adherence. Lower copayments also predicted adherence. All of our models had low 
explanatory power. Multivariate models including patient covariates only had greater explanatory 
power (C = 0.613) than models with physician variables only (C = 0.566) or copayments only (C = 
0.543). A fully specified model had only slightly more explanatory power (C = 0.633) than the model 
with patient characteristics alone.  
 
CONCLUSIONS: Despite relatively comprehensive claims data on patients, physicians, and out-of-
pocket costs, our overall ability to explain adherence remains poor. Administrative data likely do not 
capture many complex mechanisms underlying adherence. 
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ABSTRACT 
 
BACKGROUND: Although many patient, physician, and payment predictors of 
adherence have been described, knowledge of their relative strength and overall ability to 
explain adherence is limited. 
 
OBJECTIVES: To measure the contributions of patient, physician, and payment 
predictors in explaining adherence to statins 
 
RESEARCH DESIGN: Retrospective cohort study using administrative data 
 
SUBJECTS: 14,257 patients insured by Horizon Blue Cross Blue Shield of New Jersey 
(BCBSNJ) who were newly prescribed a statin cholesterol-lowering medication 
 
MEASURES: Adherence to statin medication was measured during the year after the 
initial prescription, based on proportion of days covered (PDC). The impact of patient, 
physician, and payment predictors of adherence were evaluated using multivariate 
logistic regression. The explanatory power of these models was evaluated with C 
statistics, a measure of the goodness of fit. 
 
RESULTS: Overall, 36.4% of patients were fully adherent. Older patient age, male 
gender, lower neighborhood percent black composition, higher median income, and 
fewer number of emergency department (ED) visits were significant patient predictors of     3              3                         
adherence. Having a statin prescribed by a cardiologist, a patient’s primary care 
physician, or a US medical graduate were significant physician predictors of adherence. 
Lower copayments also predicted adherence. All of our models had low explanatory 
power. Multivariate models including patient covariates only had greater explanatory 
power (C = 0.613) than models with physician variables only (C = 0.566) or copayments 
only (C = 0.543). A fully specified model had only slightly more explanatory power (C = 
0.633) than the model with patient characteristics alone.  
 
CONCLUSIONS: Despite relatively comprehensive claims data on patients, physicians, 
and out-of-pocket costs, our overall ability to explain adherence remains poor. 
Administrative data likely do not capture many complex mechanisms underlying 
adherence.  
 
KEY WORDS: ADHERENCE, RELATIVE IMPORTANCE, EXPLANATORY 
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INTRODUCTION 
 
Despite advances in medical therapy, adherence to medications, or the extent to which 
patients take medications as prescribed by their health care providers, remains suboptimal 
(1, 2). In particular, although statins have been shown to yield significant reductions in 
cardiovascular mortality and morbidity (3-7), they remain significantly underused in 
patients who are prescribed them (8-14), with yearly adherence rates from 25% to 40% 
(10, 15). 
 
Current interventions to encourage adherence are at best blunt (16). The only programs 
shown to be successful are multifaceted combinations of patient education, simplified 
dosing schedules, patient-physician communication, increased follow-up and monitoring, 
and clinic schedules that improve medication access, but these programs remain costly 
and likely impractical when applied to all patients (1, 16). At the same time, although less 
frequently, innovations that reduce the patient’s share of drug costs have been proposed 
to increase adherence (17-19). A better understanding of the relative contributions of 
patient, physician, and payment-related predictors in adherence may be useful in 
understanding non-adherence and designing more practical interventions. 
 
The barriers to adherence are complex and arise from interactions among the patient, the 
physician, and the health care system (1, 20). For example, patients may fail to be 
adherent due to reasons as varied as attitudes toward their medications, out-of-pocket 
costs, side effects, the complexity of their regimens, and poor communication with their     5              5                         
physicians. Although these reasons have been incorporated into overarching theories of 
adherence and patient behavior (21-23), studies have mostly documented groups of 
predictors separately, including demographic, clinical, socioeconomic, payment, and 
provider-related factors (1, 24).  To our knowledge, no study has examined the relative 
importance of patient, physician, and payment factors in explaining adherence or the 
cumulative explanatory power of readily observable predictors. 
 
We examined the adherence of patients insured by Horizon Blue Cross Blue Shield of 
New Jersey (BCBSNJ) who were prescribed statins. Using a combination of health care 
utilization, socioeconomic, and provider data, we measured the contributions of patient, 
physician, and payment factors in adherence.  
 
METHODS 
 
Study Sample 
 
We conducted a retrospective study in the setting of a large private health insurance 
provider, Horizon BCBSNJ, which is the largest health insurer in New Jersey. Enrollees 
of the program were eligible for inclusion in the study if they filled a prescription in 
either 2004 or 2005 for a statin (atorvastatin, rosuvastatin, fluvastatin, lovastatin, 
pravastatin, or simvastatin). Because adherence is time-dependent (10), we restricted our 
cohort to patients who had not filled a statin prescription in the year prior to their first 
prescription in 2004 or 2005. All patients included were required to be continuously     6              6                         
enrolled in Horizon BCBSNJ for one year before and one year after their index date. The 
index date was defined as the first date that the patient filled a prescription for a statin.  
 
Data Sources 
   
We compiled filled-prescription information from Horizon BCBSNJ pharmacy claims 
data. Prescription information in the claims data included drug name, dosage, date 
dispensed, quantity dispensed, and days supplied. The claims data also identified the 
prescribing physician with a unique Drug Enforcement Agency (DEA) number and 
indicated whether he or she was also listed as the patient’s primary care physician (PCP). 
Prescription information also included the copayment, or the cost of each prescription 
that the patient was required to share.  
 
Horizon BCBSNJ claims data also included patient characteristics and health care 
utilization information. Patient characteristics included age, gender, zip code of 
residence, and medical conditions as coded by the International Classification of 
Diseases, 9
th Revision (ICD-9). Health care utilization information for each enrollee 
included dates of physician visits, emergency department (ED) visits, and 
hospitalizations.  
 
Data on aggregate patient socioeconomic status as a proxy for individual socioeconomic 
status was obtained by linking patient zip code of residence with the United States 
Census, which specified the median income and racial composition of the geographic     7              7                         
population associated with the zip code of residence for each patient. Physician specialty 
and years in practice were obtained by linking the DEA number of the physician who 
prescribed the patient’s index statin with data from the AMA Physician Database 
obtained through a private intermediary (PracticeMatch, Saint Louis, Missouri).  
 
The study was approved by the Institutional Review Board of Brigham and Women’s 
Hospital. Permission was obtained from Horizon BCBSNJ to use their claims data. All 
unique patient identifiers were removed from the data prior to analysis. 
 
Measure of Adherence 
 
We constructed a continuous measure of statin adherence (25), the proportion of days 
covered (PDC), which we defined as the number of days that the statin was in the 
patient’s possession (based on filled prescriptions), from the index date to one year after 
the index date, divided by the number of outpatient days in the interval. We then defined 
a patient to be “fully adherent” if the patient had a PDC of at least 80% (8, 10). 
 
Potential Predictors of Adherence 
 
We categorized potential predictors of adherence into groups related to the patient, the 
prescribing physician, and the out-of-pocket cost of the prescription. Patient-related 
factors were evaluated during the 12 months prior to the index date and included patient 
age in decades, gender, neighborhood median income in quartiles, neighborhood percent     8              8                         
black or African American composition, number of other prescriptions written, number 
of outpatient physician visits, number of ED visits, and number of hospitalizations. 
 
We determined whether patients had evidence of an acute coronary syndrome 
hospitalization within 30 days prior to their index date or whether they had any other 
less-acute evidence of coronary artery disease (i.e., prior angina, coronary angiography, 
coronary artery bypass graft, stent, percutaneous transluminal coronary angioplasty, or 
coronary artery disease not otherwise specified). For each patient, we determined the 
number of medical comorbidities, specified as hypertension, diabetes, heart failure, 
stroke, peripheral vascular disease, chronic obstructive pulmonary disease, chronic 
kidney disease, or malignancy, and the existence of any psychiatric comorbidities, 
defined as dementia, depression, psychosis, or schizophrenia. Medical and psychiatric 
comorbidities were identified using ICD-9 diagnosis and procedure codes (available from 
the authors upon request). 
 
For the prescribing physicians, we considered the number of decades in practice from 
residency training, whether the physician was a cardiologist, whether the physician was 
also the patient’s PCP, whether the physician and the patient had the same sex, and 
whether the physician was a US medical graduate. Forty-five percent of the sample did 
not have a record of their PCP, which reflects the fact that many patients were in plan 
types that did not require a record of a PCP in the administrative data, despite the fact that 
a PCP may exist.  Of seven plan types, three had missing PCP rates less than 10%: health 
maintenance organization (HMO), point of service (POS), and Medicare. The remaining     9              9                         
four were all more expensive plans and had missing PCP rates greater than 70%: 
preferred provider organization (PPO), traditional indemnity, “Horizon Direct Access,” 
and “Exclusive Provider Organization” (EPO). To account for this, we allowed for three 
comprehensive and mutually exclusive categories of the PCP variable, “PCP unknown,” 
“PCP was index prescriber,” and “PCP was not index prescriber,” in order to use the full 
sample and adjust for possible bias by only considering patients with a known PCP.  
 
For prescription cost-sharing, we considered the total costs shared by the patient divided 
by the number of days supplied, in order to account for the fact that patients who filled 
more statin prescriptions would naturally have higher total cost-sharing. Our measure of 
cost-sharing therefore reflected the out-of-pocket cost per day of prescribed statin. 
 
Statistical Analysis 
 
To study the contribution of each category of predictors, we constructed 7 sets of 
multivariate logistic regression models: only patient variables; only physician variables; 
only daily averaged cost-sharing; patient and physician variables; patient and payment 
variables; physician and payment variables; patient, physician, and payment variables 
(Table 2). We clustered the data by the index prescriber whenever applicable (e.g. when 
both patient- and physician-level data were included in the model) using generalized 
estimating equations with an independent covariance matrix (26). The primary purpose of 
separate sets of regression models was to evaluate increases in explanatory power when 
adding categories of predictors.      10              10                         
 
For each model, we estimated the effect of each of their respective variables by an odds 
ratio, along with an associated 95% confidence interval. We also calculated the C statistic 
in order to measure the model’s ability to discriminate whether patients with certain 
characteristics will be fully adherent or not. The C statistic represents the area under the 
receiver operating characteristic curve (27). A C statistic value of 0.5 indicates that a 
model does not have any increased discriminatory power over a random coin toss to 
classify whether a patient will be fully adherent or not, whereas a C statistic value of 1.0 
represents perfect discriminatory power. For example, the Framingham Coronary Heart 
Disease Prediction Score has been found to have a C statistic between 0.63 and 0.83 
when validated in different cohorts (28). While the C statistic is a useful summary 
measure of discriminatory power, we also report rates of full adherence for the highest 
and lowest deciles as ranked by each model in order to reflect model performance across 
the distribution of patients, specifically at the high and low ends of the spectrum. Finally, 
we calculated Hosmer-Lemeshow statistics, which test the null hypothesis of proper 
calibration across all deciles, for each model (29).  
 
We used the Wald statistical test to estimate p values for maximum likelihood estimates, 
considering p values less than 0.05 to indicate statistical significance. We also used the 
Wald statistical test to estimate the 95% confidence intervals around odds ratio estimates. 
All analyses were conducted using SAS (Version 9.1, Cary, North Carolina). 
 
RESULTS     11              11                         
 
The overall study sample included 14,257 patients. Patients of this cohort had a mean age 
of 51.6 years, were 45.2% female. Median neighborhood percent black composition was 
4.4%, and median neighborhood median income was $57,900 (the respective means for 
these measures were 12% and $59,800). Of these patients, 8.77% of them had a history 
coronary heart disease; 1.26% had a history of acute coronary syndrome; the average 
number of comorbidities was 0.65; and 3.63% had a psychiatric comorbidity. Averaged 
over the cohort of patients, the number of ER visits was 0.15 per patient; the number of 
hospitalizations was 0.11 per patient; the number of physician visits was 4.16 per patient; 
and the number of concomitant medications was 5.33 per patient. The average copayment 
for the prescribed statin was $0.37 per day. The index prescriber was their primary care 
provider for 31.8% of the patients overall, or 56.7% of patients with a known primary 
care provider; the index prescriber was a cardiologist for 13.2% of the patients. The 
average index prescriber had been in practice for 23.8 years. Table 1 compares baseline 
characteristics for patients who were fully adherent and those who were not. 
 
Of the patients in our cohort, 36.4% were fully adherent. Figure 1, a plot of PDC values 
across the entire distribution of patients, shows considerable variation in adherence 
measured as PDC but also confirms an expected coarseness in the measure as most 
prescriptions are prescribed in at least monthly intervals. Our binary definition of full 
adherence is indicated by the vertical line in Figure 1. Patient, prescription, cost-sharing, 
and index-prescriber characteristics are presented separately for adherent and non-
adherent patients in Table 1.     12              12                         
 
Predictors of adherence 
 
Table 2 summarizes the odds ratios for predictors of adherence in the range of models 
that we considered. Older patient age (OR 1.34 per decade, 95% CI 1.28-1.40) and higher 
neighborhood median income (OR 1.13 per quartile, 95% CI 1.09-1.17) both were 
statistically significant predictors of full adherence. Female gender (OR 0.89, 95% CI 
0.81-0.97), higher neighborhood percent black composition (OR 0.88 per quartile, 95% 
CI 0.85-0.91) were statistically significant predictors of non-adherence. In addition, an 
index prescription close to an episode of acute coronary syndrome was associated with 
significantly higher rates of adherence (OR 1.68, 95% CI 1.18-2.38), while higher 
additional ED visits were associated with lower rates of adherence (OR 0.87 for each 
visit, 95% CI 0.80-0.94).  
 
Certain types of physician prescribers were noted to be associated with greater rates of 
adherence among their patients. For patients with a known PCP, those who had their 
index prescription written by their PCP were significantly more likely to be fully 
adherent than patients whose known PCP did not write their index prescription (OR 1.12, 
95% CI 1.02-1.25). Patients without a known PCP, who were mostly in more expensive 
plans, were also more likely to be fully adherent than patients with a known PCP who did 
not write the index prescription (OR 1.21, 95% CI 1.10-1.33). Controlling for PCP status, 
having a cardiologist as the index prescriber was independently associated with 
significantly higher adherence (OR 1.26, 95% CI 1.12-1.40). US medical graduates were     13              13                         
significantly associated with higher rates of adherence (OR 1.32, 95% CI 1.22-1.42). 
Finally, although patient-physician sex concordance missed statistical significance at the 
95% confidence level in the full model, sex concordance was associated with higher rates 
of adherence that were statistically significant in models that did not include other patient 
characteristics. 
 
Higher average copayment per day of prescribed statin, the only payment-related 
predictor, was associated with lower rates of adherence (OR 0.54 per copay daily dollar, 
95% CI 0.47-0.60). 
 
Although not shown in our Table 2, we also ran the full model with an additional 8 
interaction terms: between copayment and 4 patient characteristics (neighborhood percent 
black composition, psychiatric comorbidity, coronary heart disease older than 30 days, 
and acute coronary syndrome within 30 days), and between PCP status and these same 4 
patient characteristics. All of the odds ratios for these interaction terms were insignificant 
except for copayment and percent black, which was 0.83 and significant (95% CI 0.75-
0.91). 
 
Explaining adherence 
 
Table 2 also reports measures of the explanatory power of each multivariate regression 
model. Multivariate models including only patient covariates had greater explanatory 
power (C = 0.613) than models with only physician variables (C = 0.566) or only     14              14                         
copayments (C = 0.543). Adding physician or payment variables to the model had little 
impact on the models’ predictive ability. The full model, which included patient, 
physician, and cost-sharing variables (but not interaction terms), yielded a C statistic of 
0.631. When ranked by propensity to be fully adherent according to this model, 50.8% of 
patients in the highest decile were fully adherent, compared to the 16.8% of patients in 
the lowest decile who were fully adherent. Hosmer-Lemeshow statistics generally 
confirmed poor calibration in addition to poor predictive ability of the models; the null 
hypothesis of proper calibration was rejected in all models except the patient-only and 
physician-only models. 
 
Although not shown in Table 2, the full model with the additional interaction terms had 
essentially the same explanatory power, with a C statistic of 0.632. 
 
DISCUSSION 
 
We examined adherence among privately insured patients with patient, physician, and 
cost-sharing data. Consistent with the literature, which reports yearly statin adherence 
rates from 25% to 40% (10, 15), we confirm that statin adherence is low (36.4%) even 
among privately insured patients who have been continuously enrolled for at least one 
year. Despite considerable variation in adherence among patients (Figure 1), our findings 
suggest that the ability to predict adherence using conventional measures is poor. In our 
fully specified model, only about half of the patients ranked in the highest decile of     15              15                         
predicted adherence actually exhibit full adherence, reflecting low population adherence 
and poor model prediction.  
 
When aggregating covariates into patient-related, physician-related, and payment-related 
predictors, we find that patient-related predictors account for the largest incremental 
explanatory power in predicting adherence. For example, older patients who live in 
neighborhoods with higher median incomes are more likely to be adherent. Patients 
generally in more expensive plans (those with missing PCPs) also had higher levels of 
adherence, possibly reflecting better health care delivery or greater preference for 
adherence. Some of these covariates are indeed clinically significant: patients with a 
recent acute coronary syndrome had odds of full adherence that were 70% greater than 
other patients.  
 
The physician-related predictors that we considered have incrementally less power in 
explaining adherence. However, we found relationships that, to our knowledge, have not 
been highlighted to the same degree as patient-related predictors in the literature. For 
example, among patients with a known PCP (those generally in HMO and POS plans), 
having the PCP write the index statin prescription is associated with higher adherence. In 
addition, an index prescription written by a cardiologist is independently associated with 
higher adherence than in patients whose index prescription was written by a non-
cardiologist, which is an effect that persists even when accounting for patient 
comorbidities and cardiovascular disease. Interestingly, measures that may reflect the 
social or cultural interaction between physician and patient, such as sex concordance and     16              16                         
the country of the physician’s medical education, are also positively correlated with 
patient adherence. 
 
Finally, we confirm previous literature that copayments are negatively correlated with 
adherence. The negative effect of copayments is quite significant, with each daily 
copayment dollar associated with a diminished odds ratio of full adherence of about 0.55. 
However, although payment-related predictors of adherence have been documented 
convincingly in the literature (12, 17, 18, 24, 30), we show that the explanatory power of 
copayments is actually lower than the other two categories – patient-related and 
physician-related predictors – that we consider. This low explanatory power may be due 
to the fact that the variation of copayments is appropriately low among the privately 
insured patients that we studied. 
 
There are some limitations to our paper. First, we restricted our attention to patients in the 
private insurance setting of Horizon BCBSNJ, a population that was primarily employed, 
non-elderly, and with good drug insurance. In addition, we did not broaden our inclusion 
criteria to allow for patients who have been enrolled for intervals of less than one year. 
Similarly, as in other studies of adherence, we restrict attention to adherence after the 
initiation of treatment (8, 9, 12, 14), while it has been shown that adherence can fluctuate 
over the longer-term, with some patients becoming more adherent after initial non-
adherence (31). The prevalence and determinants of adherence likely differ among 
patient populations and health care arrangements, and findings may need to be confirmed 
in separate or more comprehensive populations. For example, although we found no     17              17                         
relationship between psychiatric comorbidity and adherence among our patients, 
psychiatric conditions such as depression have been found in other studies to be 
correlated with poor adherence (32, 33). Similarly, payment-related reasons may feature 
more prominently among patients in plans with higher variation in copayments, or among 
patients who are poorer, less educated, or lack drug insurance.  
 
Second, there is likely to be measurement error in identifying non-adherence. Using 
claims based data, we chose the proportion of days covered (PDC) as our primary metric 
and arbitrarily defined adherence as binary measure by setting a PDC cutoff of 80% 
(Figure 1). This definition has been used elsewhere (8, 10), and our findings do not 
change much when using different percentage cutoffs in PDC to define full adherence. 
However, there are a multitude of other instruments, some with finer resolution, some 
more direct than others, but none of which is a gold standard (1). Of course, it would 
ultimately be very difficult to ascertain with full certainty whether a patient is actually 
taking or “adhering to” a medication, and any measurement error would bias the 
significance levels of the odds ratios and the explanatory power of the models to the null 
hypothesis. Alternatively, we may view adherence as a sequence of behaviors, of which 
refilling prescriptions is a part. In the context of refilling medications, the PDC is a much 
more accurate measure. 
 
Lastly, although our data were fairly comprehensive in the limited sense of administrative 
data, there undoubtedly remain numerous variables unobservable to us and omitted in our 
analysis. As described above, we were unable to identify the PCP for a significant     18              18                         
proportion of patients, although our results did not change when excluding these patients. 
We could not account for practice characteristics, such as support staff or electronic 
medical record systems that might encourage adherence. We could not identify physician 
race, individual patient race, or patient language and therefore could not estimate the 
effect of racial or cultural interactions. We could not approximate the quality of the 
physician-patient relationship with variables such as the number of missed appointments 
or the length of time the patient has known the prescriber (31). Indeed, perhaps the most 
important correlates to adherence, such as physician-patient communication, 
understanding, social support, satisfaction and trust (22, 23, 34-36), may not be 
obtainable from administrative databases.  
 
These findings and limitations suggest that better data need to be collected to identify and 
understand non-adherence. Readily observable correlates may be inadequate in 
describing and predicting adherence, and a better explanatory model of adherence may 
have to account for factors that are more difficult to measure, such as patient 
understanding and the physician-patient relationship. Of course, the finding of low 
explanatory power in a study must distinguish between what is unobservable to the 
statistician and what is unobservable to the physician, since the information available to 
the clinician is naturally richer. However, the fact that even physicians perform poorly at 
predicting the adherence of their patients implies that much of non-adherence is difficult 
to observe at the individual level (1). From a clinical perspective, our immediate findings 
imply that administrative data would be insufficient to identify and describe non-
adherence, and that the most cost-effective way to identify non-adherence may still be for     19              19                         
clinicians to ask their patients about adherence on a routine basis. As we have done here 
with administrative data, simple clinical tools to identify adherence should be tested for 
predictive power. 
 
Systematic and in-depth evaluation of the predictors of non-adherence may ultimately 
reveal a heterogeneous phenomenon that cannot be completely explained or predicted by 
any single model. Unobservable determinants and heterogeneity make our models 
particularly unsuited to identifying highly adherent patients. However, it is important to 
note that the presence of multiple risk factors can still imply high risk for non-adherence. 
Even with our relatively crude model, we are able to identify patients who are very 
unlikely to be adherent; in our fully specified model, patients ranked in the lowest decile 
have only a 16.8% likelihood of full adherence. The practical implication is that even 
with models of poor predictive ability, most if not all patients should be screened for non-
adherence. In addition, although much of adherence is still unexplained, we have 
identified several correlates that deserve further investigation. For example, the positive 
effect of PCP prescribing on adherence may be explained by a good physician-patient 
relationship or by better practice-wide coordination. Similarly, the positive effect of a 
cardiologist prescribing the index statin may reflect the importance of expertise for 
patient understanding or trust, or it may be related to greater familiarity and support 
systems for patients with cardiovascular conditions. 
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FIGURE LEGEND 
 
FIGURE 1: The distribution of the proportion of days covered (PDC) for statin 
prescriptions across the sample of patients is illustrated in this figure. The cumulative 
percentage of patients with a PDC up to any given level is shown, starting from a PDC of 
0% and increasing to a PDC of 100%. A line at the 80% PDC indicates our definition of 
full adherence. August 4, 2009 
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suggested, we have changed the rows corresponding to the neighborhood percent 
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    Not Fully Adherent  Fully Adherent  All 
    N = 9,062  N = 5,195  N =14,257 
Patient Variables       
  Mean age in years (SD)
*  50.7 (8.66)  53.1 (7.48)  51.6 (8.33) 
  % female gender
*  46.5%  43.0%  45.2% 
  Median neighborhood % black or 
African American (interquartile 
range)
* 
5.2%  
(1.8-16%) 
3.7%  
(1.3-10%) 
4.4% 
(1.6-14%) 
  Median neighborhood median income 
(interquartile range)
* 
$56,300  
($44,300-69,000) 
$60,600 
($49,400-73,500) 
$57,900 
($45,600-70,600) 
  % with CHD > 30 days  8.46%  9.32%  8.77% 
  % with ACS < 30 days
*  1.03%  1.67%  1.26% 
                                                 
* Variable shows statistically significant difference (p-value < 0.05) between patients who are fully adherent and those who are not fully adherent. 
Table  Mean number of comorbidities (SD)  0.65 (0.86)  0.66 (0.89)  0.65 (0.87) 
  % with Psychiatric comorbidity  3.62%  3.64%  3.63% 
  Mean number of emergency 
department (ED) visits (SD)
* 
0.17 (0.55)  0.12 (0.55)  0.15 (0.55) 
  Mean number of physician visits (SD)  4.19 (5.70)  4.09 (6.27)  4.16 (5.92) 
  Mean number of other medications 
(SD)
* 
5.43 (5.54)  5.15 (5.51)  5.33 (5.53) 
  Mean number of hospitalizations 
(SD) 
0.11 (0.45)  0.11 (0.43)  0.11 (0.45) 
Payment Variable       
  Mean copay per day (SD)
*  $0.40 ($0.34)  $0.34 ($0.28)  $0.37 ($0.32) 
Physician Variables       
  Mean years of practice of index 
prescriber (SD) 
23.8 (9.67)  23.8 (9.47)  23.8 (9.59)  
  % with index prescriber as 
cardiologist
* 
11.9%  15.6%  13.2% 
  % with index prescriber as PCP (not 
including those with unknown PCP)
 * 
56.2%  57.2%  56.7% 
  % with index prescriber as PCP
* 
(including those with unknown PCP) 
32.6%  30.5%  31.8% 
  % with same sex as index prescriber
*  58.0%  61.1%  59.1% 
  % with index prescriber as US 
medical graduate
* 
56.1%  64.2%  59.1% 
               1 
               
       
TABLE 2: ADJUSTED ODDS RATIOS (WITH 95% CONFIDENCE INTERVALS) AND EXPLANATORY POWER BY 
MODEL
* 
 
 
  Patient Model  Payment 
Model 
Physician 
Model 
Patient, 
Payment 
Model 
Patient, 
Physician 
Model 
Payment, 
Physician 
Model 
Full Model 
Patient Variables               
  Age (per additional decade)  1.36 
(1.30, 1.41)      1.35 
(1.29, 1.41) 
1.35 
(1.29, 1.40)    1.34 
(1.28, 1.39) 
  Female gender
†  0.85 
(0.79, 0.92)      0.86 
(0.79, 0.92) 
0.88 
(0.80, 0.97)    0.88 
(0.80, 0.97) 
  Neighborhood percent 
black or African American 
(per quartile increase) 
0.86 
(0.83, 0.89)      0.86 
(0.83, 0.89) 
0.88 
(0.85, 0.91)    0.88 
(0.85, 0.91) 
  Neighborhood median 
income (per quartile 
increase) 
1.13 
(1.09, 1.17)      1.14 
(1.10, 1.18) 
1.12 
(1.08, 1.16)    1.13 
(1.08, 1.17) 
  Coronary artery disease > 
30 days
† 
0.98 
(0.85, 1.13)      0.98 
(0.85, 1.13) 
0.92 
(0.79, 1.07)    0.92 
(0.79, 1.07) 
  Acute coronary syndrome < 
30 days
† 
1.70 
(1.19, 2.41)      1.70 
(1.20, 2.42) 
1.67 
(1.17, 2.38)    1.68 
(1.18, 2.40) 
  Number of comorbidities 
(per additional comorbidity) 
1.02 
(0.97, 1.07)      1.02 
(0.97, 1.07) 
1.03 
(0.97, 1.08)    1.02 
(0.97, 1.07) 
  Psychiatric comorbidity
†  1.05 
(0.86, 1.27)      1.06 
(0.87, 1.29) 
1.02 
(0.83, 1.25)    1.04 
(0.85, 1.27) 
                                                 
* Unless otherwise indicated, variables were included as continuous linear predictors. Where useful, we indicate the unit of linear increases in parentheses. 
† Referent for these variables is the lack of the specified condition. 
Table              2 
               
       
 
  Patient Model  Payment 
Model 
Physician 
Model 
Patient, 
Payment 
Model 
Patient, 
Physician 
Model 
Payment, 
Physician 
Model 
Full Model 
  Number of emergency 
department (ED) visits (per 
additional visit) 
0.86 
(0.78, 0.96)      0.86 
(0.78, 0.96) 
0.86 
(0.78, 0.96)    0.87 
(0.78, 0.96) 
  Number of physician visits 
(per additional visit) 
1.00 
(0.99, 1.01)      1.00 
(0.99, 1.01) 
1.00 
(0.99, 1.01)    1.00 
(0.99, 1.01) 
  Number of other 
medications (per additional 
medication) 
1.00 
(0.99, 1.01)      0.99 
(0.99, 1.00) 
1.00 
(0.99, 1.01)    0.99 
(0.99, 1.00) 
  Number of hospitalizations 
(per hospitalization) 
1.00 
(0.91, 1.10)      1.01 
(0.91, 1.11) 
1.00 
(0.91, 1.11)    1.01 
(0.91, 1.12) 
Payment Variable               
  Copay (per additional dollar  
per day)    0.56 
(0.50, 0.62)    0.55 
(0.49, 0.61)    0.53 
(0.48, 0.60) 
0.54 
(0.48, 0.60) 
Physician Variables               
  Years of practice (per 
additional decade)      1.00 
(0.96, 1.04)    0.99 
(0.95, 1.03) 
1.00 
(0.96, 1.04) 
0.99 
(0.95, 1.03) 
  Index prescriber is 
cardiologist
‡      1.40 
(1.26, 1.55)    1.26 
(1.13, 1.40) 
1.39 
(1.26, 1.55) 
1.25 
(1.12, 1.40) 
  PCP is unknown
‡      1.29 
(1.18, 1.42)    1.17 
(1.07, 1.29) 
1.34 
(1.23, 1.47) 
1.21 
(1.10, 1.33) 
  Index prescriber is PCP
**      1.13 
(1.02, 1.26)    1.13 
(1.01, 1.25) 
1.13 
(1.02, 1.26) 
1.12 
(1.01, 1.25) 
  Index prescriber is same sex 
as patient
†      1.12 
(1.05, 1.21)    1.04 
(0.95, 1.14) 
1.13 
(1.05, 1.21) 
1.04 
(0.95, 1.14) 
                                                 
‡ The referent is that the PCP is known and is not the index prescriber.               3 
               
       
 
  Patient Model  Payment 
Model 
Physician 
Model 
Patient, 
Payment 
Model 
Patient, 
Physician 
Model 
Payment, 
Physician 
Model 
Full Model 
  Index prescriber is US 
medical graduate
†      1.42 
(1.31, 1.54)    1.32 
(1.22, 1.43) 
1.42 
(1.31, 1.54) 
1.32 
(1.22, 1.43) 
Explanatory Power               
  C Statistic  0.613  0.543  0.566  0.624  0.620  0.585  0.631 
  Full adherence in lowest-
ranked decile  19.7%  26.9%  36.6%  18.6%  19.0%  24.8%  16.8% 
  Full adherence in highest-
ranked decile  49.6%  37.8%  44.4%  49.9%  50.8%  46.6%  50.8% 
 